PhotoCure Delivers Strong Q2 2025 Results
PhotoCure Delivers Strong Q2 2025 Results 🕓 Estimated Reading Time: 4 minutes PhotoCure ASA reports robust financial performance in Q2 2025, significantly exceeding expectations. Hexvix®/Cysview® global sales demonstrate impressive growth, driven by strong uptake in key markets. The company achieves substantial profitability, underscoring effective commercial strategies and operational efficiency. Management provides an optimistic outlook for the remainder of 2025, reaffirming commitment to expanding bladder cancer diagnostics. Positive trends highlight PhotoCure's strengthening position in the specialized urology market. Overview Oslo, Norway – PhotoCure ASA (OSE: PHO), a leading global specialty pharmaceutical company focused on urology, announced its PhotoCure Q2 2025 financial results, revealing a period of substantial growth and increased profitability. The company reported impressive total revenues of approximately NOK 155.0 million for the second quarter ended June 30, 202...